London’s healthtech Habitual specialising in diabetes reversal closes £1.7M funding to take up clinical trials

Besides COVID-19, type 2 diabetes is the most pressing healthcare problem faced by many right now. In the UK, it is estimated that one in 10 people over the age of 40 is diagnosed with type 2 diabetes. Of these, 60 percent are said to suffer from a complication of the disease along with major risks, including amputation, heart attack, and stroke.

Recent evidence shows that 45-60 percent of those suffering from type 2 diabetes can completely reverse the condition via a combination of diet and behavioural changes. This reversal has the potential to not only change millions of lives across the world but also to save healthcare systems billions of pounds. These interventions have been delivered on a small scale for research and in NHS pilots.

London-based digital health startup Habitual is working hard to deliver a scaled digital intervention to millions of patients in need of it. The company provides digital prediabetes and type 2 diabetes remission programmes that help patients to reverse disease and live medication-free.

Today, Habitual announced it has closed $2.3 million (nearly £1.7 million) in a seed funding round led by Berlin-based early-stage investor Atlantic Food Labs along with existing investors Seedcamp and MMC. Also, Oxford Seed Fund, an initiative of the Entrepreneurship Centre at Saïd Business School, University of Oxford took part in the round.

Click here to read the full article.